Study results presented for the first time in the scientific sessions of this year’s American Diabetes Association Annual Meeting (ADA), show clinically relevant and statistically significant reductions in haemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) levels when linagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, is given as add-on therapy in type 2 diabetic patients inadequately controlled with metformin.
Furthermore, these phase II study results show a placebo-like
safety and tolerability profile under these therapeutic conditions. Notably, in the study no case of hypoglycaemia was recorded with linagliptin treatment.
“To date, metformin is the most widely used oral therapy in type 2 diabetes. However, many patients do not achieve adequate glycaemic control with metformin alone. As HbA1c and FPG levels are key diagnostic indicators for effective management of type 2 diabetes, the significant efficacy results together with the favourable safety profile shown in this trial for the investigational drug linagliptin are very encouraging. Based on the results seen to date, we are very confident that linagliptin, if approved, can provide additional benefit to patients with type 2 diabetes”, said Dr Manfred Haehl, MD, senior vice-president medicine at Boehringer Ingelheim headquarters.
Type 2 diabetes is a progressive chronic condition which frequently requires long-term treatment. Physicians treating patients with type 2 diabetes need to have a range of treatment options, including combination regimens, so they can tailor the therapy to the individual patients need and response. Results are awited from additional ongoing studies that will further assess the full potential of linagliptin for the treatment of type 2 diabetes.